• Merck (NYSE:MRK) has closed its acquisition of Terns Pharmaceuticals, adding TERN-701, a chronic myeloid leukemia drug with FDA Breakthrough Therapy Designation, to its oncology pipeline.
• The company has also published new research on biocatalytic synthesis for enlicitide decanoate, a first in class oral PCSK9 inhibitor candidate for cholesterol management.

Merck, trading at $113.56, has a 1 year return of 48.7% and a 5 year return of 78.7%, with year to date performance of 6.7%. Against that backdrop, these new oncology and cardiometabolic assets give investors more detail on what is driving interest in NYSE:MRK beyond headline products.

For shareholders watching the eventual KEYTRUDA patent expiry, both the Terns deal and the PCSK9 synthesis work highlight where future revenue contributors could come from. These updates can help you assess how Merck is building out its pipeline and manufacturing capabilities, and how that might influence the company’s long term earnings mix.

Stay updated on the most important news stories for Merck by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Merck.

Quick Assessment

• ✅ Price vs Analyst Target: At US$113.56 versus a consensus target of US$129.74, the stock trades about 12% below analyst expectations.
• ✅ Simply Wall St Valuation: Simply Wall St estimates the shares are trading roughly 47% below fair value, indicating a sizable valuation gap.
• ❌ Recent Momentum: The 30 day return of about 6.0% decline shows recent pressure despite the positive pipeline news.

There is only one way to know the right time to buy, sell or hold Merck. Head to Simply Wall St's company report for the latest analysis of Merck's Fair Value..

Key Considerations

• 📊 The Terns acquisition and the oral PCSK9 synthesis work broaden oncology and cardiometabolic optionality, which may matter for life after KEYTRUDA.
• 📊 Watch how TERN-701 progresses in trials, any partnering updates on the PCSK9 candidate, and how these feed into analyst earnings and cash flow models.
• ⚠️ With 5 identified minor risks including debt levels, margin pressure and dividend coverage, check whether additional R&D and deal spending strain the balance sheet.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Merck analysis. Alternatively, you can check out the community page for Merck to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.